Table 5.
Hypothetical trials analysis
| Population and intervention | Event number, control/intervention |
NNT for composite endpoint |
||||||
|---|---|---|---|---|---|---|---|---|
| Non-fatal Stroke |
Non-fatal MI |
Vascular death |
NNTevent | NNTDALY[3, 1] |
NNTDALY[3, 0] |
NNTDALY[0, 0] |
||
| Population at equal risk for Stroke and MI |
||||||||
| Stroke effective | 160/96 | 160/160 | 100/84 | 50 | 5.9 | 3.9 | 2.6 | |
| MI effective | 160/160 | 160/96 | 100/84 | 50 | 7.8 | 4.9 | 3.0 | |
| Population at unequal risk for Stroke and MI |
||||||||
| Stroke prone population, age 60 | ||||||||
| Stroke effective | 160/96 | 80/80 | 80/64 | 50 | 5.9 | 3.9 | 2.6 | |
| MI effective | 160/160 | 80/48 | 80/72 | 100 | 15.6 | 9.7 | 6.1 | |
| MI prone population, age 50 | ||||||||
| Stroke effective | 80/48 | 160/160 | 80/72 | 100 | 8.5 | 6.6 | 3.9 | |
| MI effective | 80/80 | 160/96 | 80/64 | 50 | 5.7 | 4.2 | 2.3 | |
For each hypothetical trial, assumptions of age onset, event rate, and relative risk reduction by treatment were described in supplementary text.
DALY[3,0]: age-weihting removed, DALY[0,0]: both future discounting and age weighting removed